Cystoscopy Articles & Analysis
13 news found
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. The biotechnology company said its next step will be to communicate with the Food and Drug Administration on the study’s results and the pathway forward to seeking regulatory approval ...
Medeon Biodesign, Inc. (TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment option for patients who are ...
First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates REDWOOD CITY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it now has five ...
Cxbladder Monitor will be used to identify those patients who can safely forego or defer a flexible cystoscopy at their next scheduled hospital visit. Once implemented, the service will be extended to use Cxbladder Triage for the evaluation of patients referred to urology for investigation of haematuria (blood in the urine and a key indicator of bladder cancer). ...
The company’s first technology under development is a promising new minimally invasive procedure that allows patient-oriented therapy via flexible cystoscopy and does not preclude future treatment ...
About the LUMINELLE DTx System The LUMINELLE DTx System is FDA cleared for both diagnostic and therapeutic hysteroscopy and cystoscopy. Health professionals can perform office evaluations and treatments of the uterus and bladder pathologies without a prohibitive investment in equipment. ...
The first abstract titled, “Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck in NMIBC surveillance,” shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder ...
The analysis, titled “Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model,” was published in the peer-reviewed journal Bladder Cancer. ...
The LUMINELLE DTx System is FDA cleared for both diagnostic and operative hysteroscopy and cystoscopy. Health professionals can perform office procedures for uterine, bladder health, without a prohibitive investment in equipment and provides convenience to office staff and patients, cost savings and addresses limitations with current disposable devices on the market. ...
About the LUMINELLE DTx System The LUMINELLE DTx System is FDA cleared for both diagnostic and therapeutic hysteroscopy and cystoscopy. Health professionals can perform office evaluations and treatments of the uterus and bladder pathologies without a prohibitive investment in equipment. ...
It also offers an alternative to urine cytology and may reduce or even replace highly invasive examinations such as cystoscopies. Bladder cancer is the sixth most commonly occurring cancer in men. ...
ByOncoDiag
Monitoring for cancer recurrence in patients with NMIBC requires patients to regularly undergo up to four invasive cystoscopies per year, which are painful procedures and require substantial resources from healthcare providers. ...
Monitoring for cancer recurrence in patients with NMIBC requires patients to regularly undergo up to four invasive cystoscopies per year, which are painful procedures and require substantial resources from healthcare providers. ...